Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016


  • Products Id :- GMDHC8464IDB
  • |
  • Pages: 396
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016', provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)

- The report reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Graft Versus Host Disease (GVHD) therapeutics and enlists all their major and minor projects

- The report assesses Graft Versus Host Disease (GVHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Graft Versus Host Disease (GVHD) Overview 11

Therapeutics Development 12

Pipeline Products for Graft Versus Host Disease (GVHD) - Overview 12

Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis 13

Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies 14

Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes 19

Graft Versus Host Disease (GVHD) - Pipeline Products Glance 21

Late Stage Products 21

Clinical Stage Products 22

Early Stage Products 23

Unknown Stage Products 24

Graft Versus Host Disease (GVHD) - Products under Development by Companies 25

Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes 30

Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development 31

AbbVie Inc 31

AbGenomics International, Inc. 32

Actelion Ltd 33

Alexion Pharmaceuticals Inc 34

Amunix Operating Inc. 35

Apceth GmbH & Co. KG 36

arGEN-X BV 37

Athersys, Inc. 38

Bellicum Pharmaceuticals, Inc. 39

Bio-Cancer Treatment International Limited 40

Biogen Inc 41

Bristol-Myers Squibb Company 42

Cantex Pharmaceuticals, Inc. 43

Capricor Therapeutics, Inc. 44

Cell2B S.A. 45

CellECT Bio, Inc. 46

Cynata Therapeutics Limited 47

Cytodyn Inc. 48

Dompe Farmaceutici S.p.A. 49

Dr. Falk Pharma GmbH 50

Escape Therapeutics, Inc. 51

F. Hoffmann-La Roche Ltd. 52

Fate Therapeutics, Inc. 53

Generon (Shanghai) Corporation Ltd. 54

Gilead Sciences, Inc. 55

GlaxoSmithKline Plc 56

Idera Pharmaceuticals, Inc. 57

ImmuNext, Inc. 58

Immunomedics, Inc. 59

Incyte Corporation 60

Kadmon Corporation, LLC 61

Kamada Ltd. 62

Kiadis Pharma N.V. 63

Kymab Limited 64

Kyorin Pharmaceutical Co., Ltd. 65

MacroGenics, Inc. 66

Mallinckrodt Plc 67

Medsenic 68

Mesoblast Limited 69

Millennium Pharmaceuticals Inc 70

Neopharm Ltd. 71

Nohla Therapeutics Inc. 72

Novartis AG 73

OncoImmune, Inc. 74

OSE Immunotherapeutics 75

Pharmicell Co., Ltd. 76

REGiMMUNE Corporation 77

Rigel Pharmaceuticals, Inc. 78

Sarepta Therapeutics, Inc. 79

Seattle Genetics, Inc. 80

Seres Therapeutics, Inc. 81

Sigmoid Pharma Limited 82

Spherium Biomed S.L. 83

Takeda Pharmaceutical Company Limited 84

Targazyme, Inc. 85

Therapix Biosciences Ltd. 86

Tobira Therapeutics, Inc. 87

Vault Pharma Inc. 88

Xenikos B.V. 89

ZIOPHARM Oncology, Inc. 90

Graft Versus Host Disease (GVHD) - Therapeutics Assessment 91

Assessment by Monotherapy Products 91

Assessment by Combination Products 92

Assessment by Target 93

Assessment by Mechanism of Action 97

Assessment by Route of Administration 101

Assessment by Molecule Type 103

Drug Profiles 105

abatacept - Drug Profile 105

AbGn-168H - Drug Profile 110

AGS-499 - Drug Profile 112

aldesleukin - Drug Profile 113

Alecmestencel-L - Drug Profile 115

alpha-1 proteinase inhibitor (human) - Drug Profile 116

ALXN-1007 - Drug Profile 120

AMX-342 - Drug Profile 122

anti-thymocyte globulin (rabbit) - Drug Profile 123

Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile 125

Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 126

ARGX-115 - Drug Profile 127

arsenic trioxide - Drug Profile 128

ATIR-101 - Drug Profile 129

BCT-200 - Drug Profile 133

begelomab - Drug Profile 134

Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile 135

Biologics for Graft Versus Host Disease - Drug Profile 136

bortezomib - Drug Profile 137

BPX-501 - Drug Profile 145

brentuximab vedotin - Drug Profile 149

budesonide - Drug Profile 173

cannabidiol - Drug Profile 176

CAP-2003 - Drug Profile 177

CD-24Fc - Drug Profile 178

Cell Therapy for Graft Versus Host Disease - Drug Profile 179

Cell Therapy for Graft-Versus Host Disease - Drug Profile 180

Cellgram for Graft Versus Host Disease - Drug Profile 181

Cellular Immunotherapy for Acute Graft Versus Host Disease - Drug Profile 182

Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile 183

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 185

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 186

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 187

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 188

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 189

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 190

Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 191

Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile 192

cenicriviroc mesylate - Drug Profile 193

CRCBT-080004 - Drug Profile 200

CX-01 - Drug Profile 201

cyclosporine CR + cyclosporine IR - Drug Profile 203

CYP-001 - Drug Profile 204

entospletinib - Drug Profile 206

F-652 - Drug Profile 208

FR-104 - Drug Profile 209

Ha-7 - Drug Profile 212

ibrutinib - Drug Profile 213

ImmuneSafe - Drug Profile 238

ImmuStem - Drug Profile 239

IMO-8400 - Drug Profile 240

IT-603 - Drug Profile 246

IT-901 - Drug Profile 247

itacitinib adipate - Drug Profile 248

KD-025 - Drug Profile 251

KRP-203 - Drug Profile 255

KY-1005 - Drug Profile 257

MAX-16H5 - Drug Profile 258

MesoStem - Drug Profile 259

methoxsalen - Drug Profile 260

MGD-010 - Drug Profile 262

milatuzumab - Drug Profile 264

Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases - Drug Profile 266

natalizumab - Drug Profile 268

nilotinib - Drug Profile 272

obinutuzumab - Drug Profile 278

OCU-300 - Drug Profile 285

Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile 286

panobinostat - Drug Profile 287

PF-05285401 - Drug Profile 295

ponesimod - Drug Profile 305

Preimplantation Factor - Drug Profile 307

PRO-140 - Drug Profile 308

ProTmune - Drug Profile 316

R-348 - Drug Profile 318

Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders - Drug Profile 320

Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile 321

Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile 322

remestemcel-L - Drug Profile 323

reparixin - Drug Profile 328

RGI-2001 - Drug Profile 331

RO-2959 - Drug Profile 333

rovalpituzumab tesirine - Drug Profile 334

ruxolitinib phosphate - Drug Profile 336

S-Graft - Drug Profile 347

SER-155 - Drug Profile 348

Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis - Drug Profile 349

Small Molecule to Inhibit Protein Kinase C Theta for Immunological Disorders and Multiple Sclerosis - Drug Profile 350

Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile 351

Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders - Drug Profile 352

sonidegib phosphate - Drug Profile 353

SP-12008 - Drug Profile 357

SYGN-305 - Drug Profile 358

Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile 359

T-Guard - Drug Profile 360

TZ-101 - Drug Profile 362

vedolizumab - Drug Profile 365

VPI-101 - Drug Profile 369

ZL-1101 - Drug Profile 370

Graft Versus Host Disease (GVHD) - Dormant Projects 371

Graft Versus Host Disease (GVHD) - Discontinued Products 376

Graft Versus Host Disease (GVHD) - Product Development Milestones 377

Featured News & Press Releases 377

Appendix 388

Methodology 388

Coverage 388

Secondary Research 388

Primary Research 388

Expert Panel Validation 388

Contact Us 388

Disclaimer 389

List of Figures

Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2016 19

Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Investigation by Universities/Institutes, H2 2016 26

Comparative Analysis by Clinical Stage Development, H2 2016 29

Comparative Analysis by Early Stage Products, H2 2016 30

Assessment by Monotherapy Products, H2 2016 98

Number of Products by Top 10 Targets, H2 2016 100

Number of Products by Stage and Top 10 Targets, H2 2016 100

Number of Products by Top 10 Mechanism of Actions, H2 2016 104

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 104

Number of Products by Top 10 Routes of Administration, H2 2016 108

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 108

Number of Products by Top 10 Molecule Types, H2 2016 110

Number of Products by Stage and Top 10 Molecule Types, H2 2016 110

List of Tables

Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2016 19

Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Development by Companies, H2 2016 (Contd..1) 22

Number of Products under Development by Companies, H2 2016 (Contd..2) 23

Number of Products under Development by Companies, H2 2016 (Contd..3) 24

Number of Products under Development by Companies, H2 2016 (Contd..4) 25

Number of Products under Investigation by Universities/Institutes, H2 2016 27

Comparative Analysis by Late Stage Development, H2 2016 28

Comparative Analysis by Clinical Stage Development, H2 2016 29

Comparative Analysis by Early Stage Development, H2 2016 30

Comparative Analysis by Unknown Stage Development, H2 2016 31

Products under Development by Companies, H2 2016 32

Products under Development by Companies, H2 2016 (Contd..1) 33

Products under Development by Companies, H2 2016 (Contd..2) 34

Products under Development by Companies, H2 2016 (Contd..3) 35

Products under Development by Companies, H2 2016 (Contd..4) 36

Products under Investigation by Universities/Institutes, H2 2016 37

Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H2 2016 38

Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International, Inc., H2 2016 39

Graft Versus Host Disease (GVHD) - Pipeline by Actelion Ltd, H2 2016 40

Graft Versus Host Disease (GVHD) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 41

Graft Versus Host Disease (GVHD) - Pipeline by Amunix Operating Inc. , H2 2016 42

Graft Versus Host Disease (GVHD) - Pipeline by Apceth GmbH & Co. KG, H2 2016 43

Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV, H2 2016 44

Graft Versus Host Disease (GVHD) - Pipeline by Athersys, Inc., H2 2016 45

Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 46

Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Limited, H2 2016 47

Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, H2 2016 48

Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company, H2 2016 49

Graft Versus Host Disease (GVHD) - Pipeline by Cantex Pharmaceuticals, Inc., H2 2016 50

Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics, Inc., H2 2016 51

Graft Versus Host Disease (GVHD) - Pipeline by Cell2B S.A. , H2 2016 52

Graft Versus Host Disease (GVHD) - Pipeline by CellECT Bio, Inc., H2 2016 53

Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Limited, H2 2016 54

Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc., H2 2016 55

Graft Versus Host Disease (GVHD) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 56

Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H2 2016 57

Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics, Inc., H2 2016 58

Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 59

Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics, Inc., H2 2016 60

Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 61

Graft Versus Host Disease (GVHD) - Pipeline by Gilead Sciences, Inc., H2 2016 62

Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H2 2016 63

Graft Versus Host Disease (GVHD) - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 64

Graft Versus Host Disease (GVHD) - Pipeline by ImmuNext, Inc., H2 2016 65

Graft Versus Host Disease (GVHD) - Pipeline by Immunomedics, Inc., H2 2016 66

Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corporation, H2 2016 67

Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corporation, LLC, H2 2016 68

Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd., H2 2016 69

Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma N.V., H2 2016 70

Graft Versus Host Disease (GVHD) - Pipeline by Kymab Limited, H2 2016 71

Graft Versus Host Disease (GVHD) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 72

Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics, Inc., H2 2016 73

Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc, H2 2016 74

Graft Versus Host Disease (GVHD) - Pipeline by Medsenic, H2 2016 75

Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Limited, H2 2016 76

Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 77

Graft Versus Host Disease (GVHD) - Pipeline by Neopharm Ltd., H2 2016 78

Graft Versus Host Disease (GVHD) - Pipeline by Nohla Therapeutics Inc., H2 2016 79

Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H2 2016 80

Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune, Inc., H2 2016 81

Graft Versus Host Disease (GVHD) - Pipeline by OSE Immunotherapeutics, H2 2016 82

Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co., Ltd., H2 2016 83

Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corporation, H2 2016 84

Graft Versus Host Disease (GVHD) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 85

Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics, Inc., H2 2016 86

Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics, Inc., H2 2016 87

Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics, Inc., H2 2016 88

Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Limited, H2 2016 89

Graft Versus Host Disease (GVHD) - Pipeline by Spherium Biomed S.L., H2 2016 90

Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 91

Graft Versus Host Disease (GVHD) - Pipeline by Targazyme, Inc., H2 2016 92

Graft Versus Host Disease (GVHD) - Pipeline by Therapix Biosciences Ltd., H2 2016 93

Graft Versus Host Disease (GVHD) - Pipeline by Tobira Therapeutics, Inc., H2 2016 94

Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc., H2 2016 95

Graft Versus Host Disease (GVHD) - Pipeline by Xenikos B.V., H2 2016 96

Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology, Inc., H2 2016 97

Assessment by Monotherapy Products, H2 2016 98

Assessment by Combination Products, H2 2016 99

Number of Products by Stage and Target, H2 2016 101

Number of Products by Stage and Mechanism of Action, H2 2016 105

Number of Products by Stage and Route of Administration, H2 2016 109

Number of Products by Stage and Molecule Type, H2 2016 111

Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2016 378

Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..1), H2 2016 379

Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..2), H2 2016 380

Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..3), H2 2016 381

Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..4), H2 2016 382

Graft Versus Host Disease (GVHD) - Discontinued Products, H2 2016 383

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AbbVie Inc

AbGenomics International, Inc.

Actelion Ltd

Alexion Pharmaceuticals Inc

Amunix Operating Inc.

Apceth GmbH & Co. KG

arGEN-X BV

Athersys, Inc.

Bellicum Pharmaceuticals, Inc.

Bio-Cancer Treatment International Limited

Biogen Inc

Bristol-Myers Squibb Company

Cantex Pharmaceuticals, Inc.

Capricor Therapeutics, Inc.

Cell2B S.A.

CellECT Bio, Inc.

Cynata Therapeutics Limited

Cytodyn Inc.

Dompe Farmaceutici S.p.A.

Dr. Falk Pharma GmbH

Escape Therapeutics, Inc.

F. Hoffmann-La Roche Ltd.

Fate Therapeutics, Inc.

Generon (Shanghai) Corporation Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Idera Pharmaceuticals, Inc.

ImmuNext, Inc.

Immunomedics, Inc.

Incyte Corporation

Kadmon Corporation, LLC

Kamada Ltd.

Kiadis Pharma N.V.

Kymab Limited

Kyorin Pharmaceutical Co., Ltd.

MacroGenics, Inc.

Mallinckrodt Plc

Medsenic

Mesoblast Limited

Millennium Pharmaceuticals Inc

Neopharm Ltd.

Nohla Therapeutics Inc.

Novartis AG

OncoImmune, Inc.

OSE Immunotherapeutics

Pharmicell Co., Ltd.

REGiMMUNE Corporation

Rigel Pharmaceuticals, Inc.

Sarepta Therapeutics, Inc.

Seattle Genetics, Inc.

Seres Therapeutics, Inc.

Sigmoid Pharma Limited

Spherium Biomed S.L.

Takeda Pharmaceutical Company Limited

Targazyme, Inc.

Therapix Biosciences Ltd.

Tobira Therapeutics, Inc.

Vault Pharma Inc.

Xenikos B.V.

ZIOPHARM Oncology, Inc.

Graft Versus Host Disease (GVHD) Therapeutic Products under Development, Key Players in Graft Versus Host Disease (GVHD) Therapeutics, Graft Versus Host Disease (GVHD) Pipeline Overview, Graft Versus Host Disease (GVHD) Pipeline, Graft Versus Host Disease (GVHD) Pipeline Assessment

select a license
Single User License
USD 2000 INR 143580
Site License
USD 4000 INR 287160
Corporate User License
USD 6000 INR 430740

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com